Natco Pharma · NSE: NATCOPHARM · BSE: 524816

Q3 FY26 results · Oct–Dec 2025

Natco Pharma reported revenue from operations of ₹647.30 crore (up 36.3% from Q3 FY25) and net profit of ₹151.30 crore (up 14.3% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY26	Q3 FY25	YoY	Q2 FY26	QoQ
Revenue from operations	647.30	474.80	+36.3%	1,363.00	−52.5%
Other income	58.10	176.30	−67.0%	100.00	−41.9%
Total income	705.40	651.10	+8.3%	1,463.00	−51.8%
Profit before share of associates & JVs and tax	161.10	163.70	−1.6%	613.70	−73.7%
Share of profit/(loss) of associates & JVs	10.90	0.00		0.00
Net profit for the period	151.30	132.40	+14.3%	517.90	−70.8%
Attributable to shareholders of the company	151.50	133.00	+13.9%	518.40	−70.8%
EPS, basic (₹)	8.46	7.43	+13.9%	28.94	−70.8%
Net margin (%)	23.4	27.9		38.0

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY26	Q3 FY25	YoY	Q2 FY26	QoQ
Revenue from operations	528.80	407.60	+29.7%	1,264.30	−58.2%
Other income	55.30	168.00	−67.1%	93.30	−40.7%
Total income	584.10	575.60	+1.5%	1,357.60	−57.0%
Profit before tax	125.20	150.30	−16.7%	586.00	−78.6%
Net profit for the period	106.90	124.90	−14.4%	500.90	−78.7%
EPS, basic (₹)	5.97	6.97	−14.3%	27.97	−78.7%
Net margin (%)	20.2	30.6		39.6

Consolidated

Filed with BSE: 12 Feb 2026, 16:49 IST
Board meeting: 12 Feb 2026
Period: 01 Oct 2025 to 31 Dec 2025
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 12 Feb 2026, 16:49 IST
Board meeting: 12 Feb 2026
Period: 01 Oct 2025 to 31 Dec 2025
Review status: Unaudited
Source: XBRL filing on BSE